chlorothiazide
Trade name: diuril
Approved
Sep 4, 1958
Like other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk. As a diuretic, chlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like chlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of chlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. It is marketed under the brand name Diuril. — NCATS
Clinical trial activity
5 trials · 5 clinical orgs · 21 marketing orgs
Earliest trial started Apr 1, 1966 (NCT00000484)
Timeline
1950s
- Sep 4, 1958
Merck — Earliest FDA Approval
- Sep 4, 1958
Akorn, Inc. — NDA Secondary Org
- Sep 4, 1958
Merck — NDA Organization
- Sep 4, 1958
Akorn, Inc. — Marketing Organization
- Sep 4, 1958
Rising Pharmaceuticals — Marketing Organization
- Dec 11, 1958
Merck — Marketing Organization
1970s
- Jul 17, 1975
PHARMOBEDIENT — Marketing Organization
- Nov 4, 1977
Watson Pharmaceuticals — Marketing Organization
- Mar 8, 1978
AmerisourceBergen — Marketing Organization
1980s
- Apr 1, 1981
Sandoz — Marketing Organization
- Jul 14, 1982
Hikma — Marketing Organization
- Sep 2, 1982
Lederle — Marketing Organization
- Sep 2, 1982
American Cyanamid — Marketing Organization
2000s
- Oct 16, 2009
Fresenius — Marketing Organization
2010s
- Jul 26, 2011
Sun Pharmaceuticals — Marketing Organization
- Apr 22, 2013
Lutipold — Marketing Organization
- Apr 22, 2013
Sankyo — Marketing Organization
- Apr 22, 2013
Daiichi Sankyo — Marketing Organization
- Jun 18, 2014
Mylan — Marketing Organization
- Jun 18, 2014
Apicore — Marketing Organization
- May 29, 2015
Sagent Pharmaceuticals, Inc. — Marketing Organization
2020s
- Oct 3, 2024
Gland Pharma Ltd — Marketing Organization
Indications
Approved for
Mechanism of action
SLC12A3 inhibitor
Combination products
aldoclor
with methyldopa
diupres
with reserpine
Also known as chlorothiazide-reserpine
Approval history
- approvedPriority reviewSep 4, 1958
Chemistry & pharmacology
SMILES
NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O- Mol. weight
- 295.73 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL842 ↗
- WikipediaChlorothiazide ↗
- NCATS77W477J15H ↗
- ChEMBLCHEMBL1200616 ↗
Also known as
- 6-chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
- 6-chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
- 6-chloro-7-sulfamoyl-2h-1,2,4-benzothiadiazine 1,1-dioxide
- 6-chloro-7-sulfamoyl-2h-1,2,4-benzothiadiazine 1,1-dioxide
- chlorothiazid
- chlorothiazid
- chlorothiazide
- chlorothiazide
- chlorothiazide
- chlorothiazide
- chlorothiazide
- chlorothiazide
- chlorothiazide
- chlorothiazide
- chlorothiazide
- chlorothiazide
- chlorothiazide
- chlorothiazide sodium
- chlorothiazide sodium
- chlorothiazide sodium
- chlorothiazide sodium
- chlorothiazidum
- chlorothiazidum
- chlorthiazide
- chlorthiazide
- chlorthiazide
- clorotiazida
- clorotiazida
- diuril
- diuril
- diuril
- mechlozid
- mechlozid
- saluric
- saluric
- uroflux
- uroflux
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03574857 | Phase 4 | Jun 30, 2018 | University of Virginia |
| NCT02606253 | Phase 4 | Feb 1, 2016 | Vanderbilt University |
| NCT02546583 | N/A | Aug 1, 2015 | Yale University |
| NCT05840536 | Phase 4 | May 31, 2014 | Ochsner Health System |
| NCT00000484 | Phase 3 | Apr 1, 1966 | National Heart, Lung, and Blood Institute (NHLBI) |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 1 | 1 | 1966 |
| Ochsner Health System | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Virginia | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2015 |
Marketing (28)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Akorn, Inc. | For profit | NDA2 | Sep 4, 1958 |
| Akorn, Inc. | For profit | MKTG | Sep 4, 1958 |
| American Cyanamid | For profit | MKTG | Sep 2, 1982 |
| AmerisourceBergen | For profit | MKTG | Mar 8, 1978 |
| Apicore | For profit | MKTG | Jun 18, 2014 |
| Daiichi Sankyo | For profit | MKTG | Apr 22, 2013 |
| Fresenius | For profit | MKTG | Oct 16, 2009 |
| Gland Pharma Ltd | For profit | MKTG | Oct 3, 2024 |
| Hikma | For profit | MKTG | Jul 14, 1982 |
| Hikma | For profit | SYN | Dec 22, 1983 |
| Hikma | For profit | SYN | Dec 22, 1983 |
| Lederle | For profit | MKTG | Sep 2, 1982 |
| Lutipold | For profit | MKTG | Apr 22, 2013 |
| Merck | For profit | NDA | Sep 4, 1958 |
| Merck | For profit | MKTG | Dec 11, 1958 |
| Mylan | For profit | SYN | Jul 17, 1975 |
| Mylan | For profit | MKTG | Jun 18, 2014 |
| PHARMOBEDIENT | For profit | MKTG | Jul 17, 1975 |
| Par Pharmaceuticals | For profit | MKTG | — |
| Rising Pharmaceuticals | For profit | MKTG | Sep 4, 1958 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | May 29, 2015 |
| Sagent Pharmaceuticals, Inc. | For profit | SYN | May 29, 2015 |
| Salix | For profit | NDA2 | Oct 6, 1961 |
| Sandoz | For profit | MKTG | Apr 1, 1981 |
| Sankyo | For profit | MKTG | Apr 22, 2013 |
| Sun Pharmaceuticals | For profit | SYN | Jul 26, 2011 |
| Sun Pharmaceuticals | For profit | MKTG | Jul 26, 2011 |
| Watson Pharmaceuticals | For profit | MKTG | Nov 4, 1977 |